IREN Is Down 71%. Should You Buy the Dip?
IREN has fallen 71% despite AI Cloud revenue rising from $7.3 million to $200 million quarterly and more than $20 billion in contracted backlog.
IREN has fallen 71% despite AI Cloud revenue rising from $7.3 million to $200 million quarterly and more than $20 billion in contracted backlog.
What an interesting question... is there a repeatable "tough industry" playbook which creates value over time? $DDS is a share cannibal with an ugly looking revenue picture (no growth from 1998-2026 / declining) https://t.co/v8YKS28dN9 https://t.co/7e3nlBYuad
Small Bay Industrial investors will do everything in SoCal instead of buying $REXR If you’re looking to deploy more than 7 figures in SoCal smallbay industrial, $REXR is much cheaper and literally selling some warehouse to the aggressive buyers Using proceeds to buy back shares further boosting intrinsic value Crazy public arbitrage of private market value DM open if you actually want to get more than 7 figures of exposure to SoCal warehouse
Just got a Pokemon rip offer in the Dunkin Donuts app. $GME is a sleeping giant. https://t.co/8QDb89DOJu
Dillard's $DDS is an interesting case study on shareholder value creation in the face of enormous industry headwinds. My question - is there a repeatable "tough industry" playbook here, or were there one-off factors that allowed it to occur? https://t.co/SkggeTE4cY
Softening Colombian Peso, falling interest rates, tariffs going away. Perfect set-up brewing. $TGLS https://t.co/3UHXULRh5V https://t.co/FkvlubmoV8
Continue reading here for the three gaps $FTEK’s new CEO wants acquisitions to fill: https://t.co/bGd410P4Lq
Floor & Decor’s 3Q26 sales rose 3% while comparable sales fell 1.4%; it cut 2027 openings to 10-15 as high mortgage rates pressure…
Floor & Decor's 3Q26 sales rose 3% while comparable sales fell 1.4%; it slowed 2027 openings to 10-15 as high mortgage rates pressure…
Kimberly-Clark’s Kenvue merger targets $1.9 billion in synergies by 2029, supporting roughly 6% long-term EPS growth and continued dividend…
Blue Dolphin’s 15,000-barrel-per-day Texas refinery earned $2.18 per share in first-half 2026 as diesel shortages widened crack spreads,…
Park Hotels & Resorts grew Q3 occupancy and RevPAR as renovations supported group and leisure demand, while leverage, Hawaii exposure and…
Procore CFO Rachel Pyles discusses accelerating growth and economies of scale after an upbeat third-quarter report.
Diageo’s first quarter under CEO Dave Lewis showed modest price changes and regional growth outside North America, supporting a turnaround…
Tower Semiconductor reported $526 million in quarterly revenue and extended photonics contracts through 2029, while its low-loss silicon…
Applied Materials trades at 17.93x forward earnings, with analysts forecasting more than 45% EPS growth through 2028 and a net-cash balance…
Perimeter Group posted 24% revenue growth to $390 million as fire-safety contracts and acquisitions lifted results, while it brings PDI…
OSG · long Octave Specialty Group, formerly Ambac Financial, is pitched as a long after its municipal bond insurance past.
Warrior Met Coal’s lower-cost longwall mines and Blue Creek expansion protect cash flow, while new high-vol supply depresses Alpha…
Sezzle fell 20% after Q2 despite a revenue and EPS beat and higher guidance, as marketing spending and seasonality drove a sequential…
Trip.com dominates China’s online travel market with over 50% share and has grown international platform traffic from 1 million monthly…
Teleflex is divesting lower-growth units, using proceeds for debt reduction and buybacks while focusing on faster-growing Vascular and…
CAAP reported decent second-quarter earnings and its first dividend, while Brazil rose on an election poll and USMCA trade developments…
Moderna and Merck reported positive Phase III INTerpath-001 results for a personalized cancer vaccine, turning clinical clarity into a…
Instacart’s larger grocery baskets create disproportionately better delivery economics than DoorDash’s, making half the basket size worth…
Eton Pharmaceuticals licensed rare-disease medicines, raised revenue guidance twice and climbed more than fourfold from its February 2026…
TG Therapeutics' Briumvi growth and subcutaneous formulation progress have fueled takeover rumors, with Biogen, Incyte and Sanofi cited as…
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.